ImmunityBio Inc. News

Latest updates and market news for IBRX

7 news

Mar 1 - Mar 7, 2026

Page 1

H.C. Wainwright Raised Its Price Target on ImmunityBio, Inc. (IBRX) to $15 from $10 and Maintains a Buy Rating

Insider Monkey

a day ago

H.C. Wainwright Raised Its Price Target on ImmunityBio, Inc. (IBRX) to $15 from $10 and Maintains a Buy Rating

Forget ImmunityBio: This Big‑Cap Pharma Is the Safer Play on Next‑Gen Cancer Therapies

Motley Fool

2 days ago

Forget ImmunityBio: This Big‑Cap Pharma Is the Safer Play on Next‑Gen Cancer Therapies

📊

AI Sentiment

Positive

7/10

ImmunityBio Bladder Cancer Milestone Raises Questions On Global ANKTIVA Rollout

Simply Wall St.

2 days ago

ImmunityBio Bladder Cancer Milestone Raises Questions On Global ANKTIVA Rollout

ImmunityBio (IBRX) Is Down 5.8% After ANKTIVA Rollout Fuels Revenue Jump And Narrower Losses

Simply Wall St.

2 days ago

ImmunityBio (IBRX) Is Down 5.8% After ANKTIVA Rollout Fuels Revenue Jump And Narrower Losses

ImmunityBio, Inc. (IBRX) Price Target Raised After Strong ANKTIVA Launch

Insider Monkey

4 days ago

ImmunityBio, Inc. (IBRX) Price Target Raised After Strong ANKTIVA Launch

📈

AI Sentiment

Highly Positive

9/10

ImmunityBio Q4 Earnings Call Highlights

MarketBeat

4 days ago

ImmunityBio Q4 Earnings Call Highlights

ImmunityBio, Inc. Q4 2025 Earnings Call Summary

Moby

4 days ago

ImmunityBio, Inc. Q4 2025 Earnings Call Summary

Share this news page

Share on Social Networks: